STRO vs TXN · rev $62.0M vs P/E 52, rev $17.68B
Sutro Biopharma (STRO) versus Texas Instruments Incorporated (TXN) — a side-by-side from cached financials, not a winner call.
Sutro Biopharma (STRO) is a biotechnology company listed on NASDAQ.
Texas Instruments Incorporated (TXN) is a semiconductors company listed on NASDAQ.
Latest reported STRO revenue for 2024-12-31 was $62.0M. Net income was -$227.5M. Revenue was down 59.6% from 2023-12-31 to 2024-12-31. STRO currently screens at market cap $470.8M.
Latest reported TXN revenue for 2025-12-31 was $17.68B. Net income was $5.00B. Revenue was up 13.0% from 2024-12-31 to 2025-12-31. TXN currently screens at market cap $274.74B and trailing P/E 51.7.
STRO currently screens at market cap $470.8M. TXN currently screens at market cap $274.74B and trailing P/E 51.7.
Not investment advice. Open the STRO and TXN stock pages for the full models.
Not investment advice.